Ipilimumab

The FDA granted the combination of nivolumab and ipilimumab priority review and breakthrough therapy designation for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib, according to a company-issued press release.

Lung Cancer Awareness Month — observed every November — is intended to educate the public about the potential causes and risk factors of the disease.

The addition of nivolumab and low-dose ipilimumab to first-line chemotherapy significantly extended OS for patients with advanced non-small cell lung cancer, according to results of a prespecified interim analysis from the randomized phase 3 CheckMate -9LA trial.

BARCELONA, Spain — Nivolumab in combination with ipilimumab conferred clinical benefit for women with recurrent or metastatic cervical cancer regardless of PD-L1 status, according to results of the randomized phase 1b/phase 2 CheckMate 358 study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — A combination of nivolumab and low-dose ipilimumab significantly improved OS compared with chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer, according to results of the randomized phase 3 CheckMate 227 study presented at European Society for Medical Oncology Congress.

BARCELONA — The combination of low-dose, weight-based ipilimumab and flat-dose nivolumab demonstrated safety and efficacy as first-line treatment for patients with stage IV non-small cell lung cancer and comorbidities that traditionally preclude them from enrolling in clinical trials, according to results of the single-arm, nonrandomized CheckMate 817 study presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.